Monograph

C10AX09 - Ezetimibe

Propably not porphyrinogenic

Rationale

Probably non-CYP metabolism. No data pointing to any interaction with the metabolism of CYP-metabolised drugs.

Chemical description

Selective inhibitor of intestinal cholesterol absorbtion. Mainly metabolized in the liver and intestinal wall via glucuroidation (phase II reaction) and eliminated via bile.

IPNet drug reports

Uneventful use reported in 8 patients with acute porphyria.

Similar drugs

Explore alternative drugs in similar therapeutic classes C10A / C10AX or go back.

Tradenames

This list comprises raw data collected from different countries. In some cases, a more comprehensive list of available drug packages is included. Consequently, very similar terms may therefore appear multiple times. Bold names are the searchable terms, while the gray names that follow are all mapped to the bolded term.

Note: The cleaning is done automatically by a proprietary algorithm, and it may produce errors. We strive to improve it continuously.

Show more details and information about the listed tradenames